Neuropsychiatric Adverse Events of Varenicline: A Systematic Review of Published Reports
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Over the past years, the impact of varenicline in patients with mental illness has been debated as serious neuropsychiatric adverse events (AEs) have been reported with varenicline use. AIM: To identify and summarize published case reports of neuropsychiatric AEs ascribed to varenicline and to determine potential risk factors for these AEs. METHODS: A literature search of MEDLINE, the Cochrane Library, EMBASE, and PsychInfo database was conducted for case reports concerning the neuropsychiatric AEs of varenicline published in English from 2006 (approval year by the US Food and Drug Administration and the Dutch Medicines Evaluation Board) to January 1, 2012. RESULTS: We identified 25 published cases. In most reports, patients had been admitted to psychiatric hospitals with serious neuropsychiatric AEs due to varenicline. The average patient age was 46.4 years, and 56% were men; 68% of patients had a psychiatric history. The onset of symptoms started 2 days to 3 months after the initiation of varenicline. One report described completed suicide in a man with no psychiatric history. In most cases (84%), the neuropsychiatric symptoms resolved after the discontinuation of varenicline. Analysis of all reports using the Naranjo causality scale, a method for estimating the probability of adverse drug reactions, indicated probable causality in 76% of the cases and definite causality in 12% of cases. CONCLUSION: Varenicline is associated with an increased risk of serious neuropsychiatric AEs, especially in patients with a psychiatric illness. It is strongly recommended that varenicline be administered only to mentally stable patients and under close monitoring.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ahmed et al.40 analyzed 25 published case reports spanning from 2006, when varenicline received FDA approval, to 2012. Analysis of all reports using the Naranjo causality scale, a method for estimating the probability of adverse drug reactions, indicated probable causality in 76% of the cases and definite causality in 12% of the cases.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [40]
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Shape of the relapse curve and long-term abstinence among untreated smokers
Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414 · cited 1×
“Most smokers who try to quit smoking on their own relapse within the first week of quitting.(6,7) However, success rates can be improved if people are assisted in their attempt to quit smoking, and especially if pharmacological treatment is combined with behavioral counseling.”
BackgroundVarenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533
Benowitz, N. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.3 · Cited by 517 · cited 1×
“Nicotine stimulates the release of multiple neurotransmitters, including dopamine, serotonin, norepinephrine, acetylcholine, glutamate, endorphins, and gamma-aminobutyric acid.(63) Through direct activation of nicotinic acetylcholine receptors, specifically >4A2 receptors, varenicline stimulates the release of dopamin…”
Background
Cited by
Baker, T. B., Piper, M. E., Stein, J. H., Smith, S. S., Bolt, D. M., Fraser, D. L., & Fiore, M. C. (2016) · JAMA · doi:10.1001/jama.2015.19284 · Cited by 180
Re-evaluating the link between neuropsychiatric disorders and dysregulated adult neurogenesis
Yun, S., Reynolds, R. P., Masiulis, I., & Eisch, A. J. (2016) · Nature Medicine · doi:10.1038/nm.4218 · Cited by 128
Cancer screening, prevention, and treatment in people with mental illness
Weinstein, L. C., Stefančić, A., Cunningham, A., Hurley, K. E., Cabassa, L. J., & Wender, R. C. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21334 · Cited by 119
“”(73) In contrast, another study assessed neuropsychiatric adverse events associated with varenicline and, using a method for estimating the probability of adverse drug reactions, concluded that varenicline was responsible for probable causality in 76% of cases and definite causality in 12% of cases.(69) Although that…”
ResultEjiofor, S., & Turner, A. M. (2013) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s7211 · Cited by 57
Molero, Y., Lichtenstein, P., Zetterqvist, J., Gumpert, C. H., & Fazel, S. (2015) · BMJ · doi:10.1136/bmj.h2388 · Cited by 54
Metadata
- Authors
- Ahmed, A. I. A., Ali, A. N. A., Kramers, C., Härmark, L. V. D., Burger, D. M., & Verhoeven, W. M. A.
- Affiliations
- Erasmus MC (NL)
- Radboud University Medical Center (NL)
- University of Groningen (NL)
- Corresponding author
- Ahmed, Amir I.A.
- Verhoeven, Willem M.A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2013-02
- Volume
- 33
- Issue
- 1
- Pages
- 55-62
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2045752876
- Cited by
- 34
- References
- 49
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 8 · 2014: 8 · 2013: 3
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- varenicline, neuropsychiatric adverse effects, smoking cessation, nicotine receptor partial agonist, suicide, psychiatric comorbidity, risk factors, drug discontinuation
- MeSH terms
- Varenicline, Smoking Prevention, Adult, Aged, Mental Disorders, Benzazepines, Female, Humans, Male, Middle Aged, Quinoxalines, Risk Factors, Time Factors, Comorbidity, Smoking Cessation, Risk Assessment, Nicotinic Agonists, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuropsychiatric Adverse Events of Varenicline: A Systematic Review of Published Reports. https://app.cochat.ai/papers/10.1097/jcp.0b013e31827c0117
- The paper
- Ahmed, A. I. A., Ali, A. N. A., Kramers, C., Härmark, L. V. D., Burger, D. M., & Verhoeven, W. M. A. (2013). Neuropsychiatric Adverse Events of Varenicline: A Systematic Review of Published Reports. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31827c0117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.